We provide evidence that the CREB-CBP complex may be a potential therapeutic target in human cancers and its inhibitors may be an alternate treatment option for lung cancer patients and potentially other tumor types, including pancreatic and breast cancers. This evidence concerns the gene CREB1 and lung cancer.